Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149144 | 0.89 | TLR7 (0.57) | TLR7 | |
| SCHEMBL4149215 | 0.82 | TLR7 (0.74) | TLR7IL6 | |
| SCHEMBL4135597 | 0.77 | TLR7 (0.62) | TLR7IL6 | |
| SCHEMBL4576652 | 0.76 | TLR7 (0.69) | TLR7 | |
| SCHEMBL4576478 | 0.76 | TLR7 (0.69) | TLR7 | |
| SCHEMBL14148725 | 0.76 | TLR7 (0.48) | TLR7 | |
| SCHEMBL4140183 | 0.75 | TLR7 (0.65) | TLR7IL6 | |
| SCHEMBL4128174 | 0.75 | TLR7 (0.55) | TLR7 | |
| SCHEMBL4127425 | 0.75 | TLR7 (0.64) | TLR7IL6 | |
| SCHEMBL4130927 | 0.75 | TLR7 (0.66) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | claimed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | claimed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 389/4885IL6 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.